|
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells.
|
9398654 |
1997 |
|
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elucidation of the regulation of human sodium-iodide symporter (hNIS) gene expression is critical to understanding its effects on iodide concentration abilities of thyroid and thyroid carcinomas.
|
9492156 |
1998 |
|
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Expression of the Na+/I- symporter (NIS) gene was investigated by RT-PCR in a selected series of 26 primary thyroid carcinomas (19 papillary, 5 follicular, and 2 anaplastic).
|
9661633 |
1998 |
|
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Apart from these therapeutic and diagnostic perspectives the availability of the NIS gene will also open new opportunities to develop sensitive and homologous diagnostic test systems to identify factors involved in autoimmune thyroid disease, evolution of goitre, adenoma and thyroid cancer as well as NIS-directed new drugs.
|
9865544 |
1998 |
|
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
By immunohistochemistry, staining of hNIS protein was stronger in Graves' and toxic adenomas and reduced in thyroid carcinomas.
|
10576759 |
1999 |
|
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status.
|
10404820 |
1999 |
|
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Study of NIS gene expression in the metastatic lymph nodes, therefore, may provide useful information in the management of patients with thyroid carcinoma.
|
11078986 |
2000 |
|
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These data showed that circulating Tg mRNA is not only a more sensitive marker of residual thyroid tissue or thyroid cancer than sTg, particularly in patients during T4 therapy and with positive antithyroglobulin antibodies, but also was more sensitive than NIS mRNA in all patients.
|
11061512 |
2000 |
|
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Strategies to restore iodide uptake in thyroid cancer include the exploration of hNIS gene transfer into hNIS defective thyroid cancer.
|
11128720 |
2000 |
|
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Both up- and down-regulation of NIS gene expression have been reported in thyroid cancer using several different methods.
|
11301345 |
2001 |
|
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Strategies to restore iodide uptake in thyroid cancer include the exploration of hNIS gene transfer into hNIS defective thyroid cancer.
|
11573141 |
2001 |
|
Thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Absence of sodium/iodide symporter gene mutations in differentiated human thyroid carcinomas.
|
11272095 |
2001 |
|
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In contrast, 2 neoplastic thyroid tissues carrying undetectable PDS mRNA maintained NIS transcript, and 3 thyroid carcinomas negative for NIS mRNA retained the expression of PDS gene.
|
11454507 |
2001 |
|
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Radioiodine therapy, the most effective form of systemic radiotherapy available, is currently useful only for thyroid cancer because of thyroid-specific expression of the sodium iodide symporter (NIS).
|
11704812 |
2001 |
|
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Radioiodide uptake (RAIU) in thyroid follicular epithelial cells, mediated by a plasma membrane transporter, sodium iodide symporter (NIS), provides a first step mechanism for thyroid cancer detection by radioiodide injection and effective radioiodide treatment for patients with invasive, recurrent, and/or metastatic thyroid cancers after total thyroidectomy.
|
12477251 |
2002 |
|
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The increased NIS expression and reduced PDS expression may make radioiodine therapy more effective in patients with thyroid cancer, especially when the tumors have no or low uptake of radioiodine.
|
12490845 |
2002 |
|
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Sodium/iodide symporter (NIS) is a key protein in iodide transport by thyroid cells and this activity is a prerequisite for effective radioiodide treatment of thyroid cancer.
|
12475396 |
2002 |
|
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Radioactive iodide uptake (RAIU) in thyroid follicular epithelial cells, mediated by the sodium iodide symporter (NIS), is the first rate-limiting step in iodide accumulation which provides a mechanism for effective radioiodide treatment for patients with thyroid cancer.
|
12170377 |
2002 |
|
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Deficient CRE-like sequence binding protein(s) that bind to the hNUE in normal thyroid cells may be responsible for reduced NIS gene expression in some thyroid carcinomas.
|
12351692 |
2002 |
|
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A mammalian NIS expression vector was constructed and used to generate six stable NIS-expressing cancer cell lines (three derived from thyroid carcinoma, two from colon carcinoma, one from glioblastoma).
|
12111124 |
2002 |
|
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Several investigators have shown that gene transfer of NIS into a variety of cell types confers increased radioiodine uptake by up to several hundredfold that of controls in nonthyroid cancers as well as in thyroid cancer.
|
12215558 |
2002 |
|
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The sodium iodide symporter (NIS) mediates iodide uptake in thyroid cells and enables the effective radioiodide treatment of thyroid cancers.
|
12699587 |
2003 |
|
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Iodination of proteins in TPO transfected thyroid cancer cells is independent of NIS.
|
15062578 |
2003 |
|
Thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results have indicated for the first time that reduced levels of CREB expression are a feature of thyroid carcinomas, and confirm that different factors are likely to modulate NIS expression.
|
12720543 |
2003 |
|
Thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
NIS is a target for radioiodide imaging and therapeutic ablation of thyroid carcinomas and has the potential for similar use in breast cancer treatment.
|
15472226 |
2004 |